期刊文献+

高危非肌层浸润性膀胱癌的膀胱灌注治疗 被引量:5

下载PDF
导出
摘要 膀胱肿瘤是泌尿系统中最常见的恶性肿瘤之一[1]。世界范围内每年新发的膀胱移行细胞癌患者已超过336 000例,其中非肌层浸润性膀胱癌(non-muscle-invasivebladdercancer,NMIBC)占75%,这其中又有约20%~25%的膀胱肿瘤侵犯到黏膜下层(T1期)[2]。NMIBC根据复发风险及预后不同可分为低危(单发的Ta G1,且肿瘤直径小于3 cm)、
出处 《现代医药卫生》 2016年第3期383-386,共4页 Journal of Modern Medicine & Health
  • 相关文献

参考文献29

  • 1Jacques F , Hai-Rim S ,Freddie B ,et al. Estimates of worldwide burden of cancer in 2008 :GLOBOCAN 2008[J]. Int J Cancer,2010, 127 (12) :2893- 2917.
  • 2Rhijn BWGV , Burger M , Lotan Y , et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer:from epidemiology to treatment strategy[J]. Eur Urol ,2009 ,56(3) :430-442.
  • 3吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004.589-591.
  • 4Babjuk M ,Burger M ,Zigeuner R,et al. EAU Guidelines on non-muscleinvasive Urothelial Carcinoma of the Bladder: Update 2013[J]. Eur Urol, 2013 ,64(4) :639-653.
  • 5黄懿,丁留成,卫中庆.T_1G_3期膀胱癌保守治疗与早期根治性膀胱切除远期预后的Meta分析[J].肿瘤,2013,33(10):903-908. 被引量:3
  • 6Morales A, Eidinger D, Bruce A W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors[J]. J Urol, 1976, 116 (2Pt2) : 891-894.
  • 7Ratliff TL , Ritchey JK, Yuan JJ, et al. T-cell subsets required forintravesical BCG immunetherapy for bladder cancer [J]. J Urol, 1993 , 150 (3) : 1018-1023.
  • 8Mungan NA, Witjes JA. Bacille Calmette-Cuerinin superficial transitional cell carcinoma[J]. Br J Urol,1998,82(2) :213-223.
  • 9Bohle A, Brandau S. Immune mechanisms in bacillus Chalmette-Guerin immunotherapy for superficial bladder cancer[J]. J Urol, 2003 ,170 (3) : 964-969.
  • 10Lamn DL,Blumenstein BA,ChrismanJD,et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta , Tl and carcinomain situ transitional cell carcinoma of the bladder: a randomized South-west Oncology Group Study[J]. J Urol,2000,163(4): 1124-1129.

二级参考文献17

  • 1VAN RHIJN B W, BURGER M, LOTAN Y, et al. Recurrence and progression of disease in non- muscle-invasive bladder cancer: from epidemiology to treatment strategy[J]. Eur Urol, 2009, 56:430-442.
  • 2COOKSON M S, HERR H W, ZHANG Z F, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome[J].J Urol, 1997, 158:62-67.
  • 3PATARD J, MOUDOUNI S, SAINT F, et al. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 1 7 years[J]. Urology, 2001, 58(4):551-556.
  • 4THALMANN G N, MARKWALDER R, SHAHIN O, et al. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy[J]. J Urol, 2004, 172(1):70-75.
  • 5DENZINGER S, BURGER M, FRITSCHE H M, et al. Bladder preservation or initial cystectomy in TG3bladder cancer: which parameters help in therapeutic decision-making[J]. Aktuelle Urol, 2008, 39(1 ):58-61.
  • 6VARCA V, SIMONATO A, ESPOSITO M, et al. Early vs delayed radical cystectomy compared in highgrade superficial bladder tumors[J]. Urologia, 2009, 76(2):83-86.
  • 7HAUTMANN R E, VOLKMER I G, GUST K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3)[J].WorldJ Urol, 2009, 27(3):347-51.
  • 8DE BERARDiNIS E, BUSETTO G M, ANTONiNI G, eta/. TIG3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy[J]. Int UrolNephrol, 201 I, 43(4):I 047-I 057.
  • 9HALL M C, CHANG S S, DALBAGNI G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update[J].J Urol, 2007, 178(6):2314-2330.
  • 10HUNCHAREK M, KUPELNICK B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Gurin immunotherapy[J]. ArnJ C/in Oncol, 2004, 27(5):522-528.

共引文献1431

同被引文献41

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部